Savara, Inc.
Regulated industryPhysical productsDevelopment stageTags from an AI model reading the company description.
Key Metrics
- Previous Close
- $4.48
- 52-Week Range
- $4.13 – $7.01
- Market Cap
- $1.04B
- P/E (TTM)
- —
- EPS (TTM)
- -0.60
- Dividend Yield
- 0.00%
Advanced Metrics
- Price/Book
- 11.13
- PEG Ratio
- —
- Return on Equity
- -151.05%
- Return on Assets
- -65.72%
- Gross Margin
- 0.00%
- Operating Margin
- 0.00%
- Profit Margin
- 0.00%
- Current Ratio
- 8.55
- Debt/Equity
- 0.29
- Total Debt
- $31.57M
- Free Cash Flow
- $-73.67M
- Revenue Growth
- —
- Earnings Growth
- —
- Enterprise Value
- $1.17B
Market Snapshot
About
Savara, Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for rare respiratory diseases. The company's lead product candidate targets autoimmune pulmonary alveolar proteinosis (aPAP), a rare lung disorder. Savara is advancing novel therapies through clinical trials to address significant unmet medical needs.